The cyclical variation in VEGF levels [4,5] is likely to obscure or even eclipse tumor production of VEGF rendering serum VEGF levels unreliable as a disease marker in breast cancer, despite having proven use in predicting prognosis in a number of other cancers [23-25]. The gene discussed is VEGFA; the disease is neoplasm.